Published in Breast Cancer Res Treat on September 13, 2013
Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat (2015) 0.89
Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer (2014) 0.81
Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. Jpn J Clin Oncol (2016) 0.78
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? Eur J Nucl Med Mol Imaging (2015) 0.78
Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer. PLoS One (2016) 0.75
PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. Br J Cancer (2017) 0.75
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging (2010) 2.32
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging (2006) 2.08
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med (2004) 1.74
Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol (2011) 1.37
Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat (2011) 1.24
First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol (2006) 1.21
A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat (2011) 1.20
Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer (2012) 1.11
Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol (2011) 1.04
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat (2011) 1.00
Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer (2012) 0.98
Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging (2012) 0.95
Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Breast (2013) 0.88
Multiple (18)F-FDG, PET-CT for postoperative monitoring of breast cancer patients. Acta Radiol (2009) 0.83
Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow-up of postoperative breast cancer patients. Breast Cancer Res Treat (2011) 0.80
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. Ann Oncol (2012) 0.79
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol (2009) 3.69
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg (2005) 2.84
Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study. J Thorac Cardiovasc Surg (2013) 2.65
Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg (2012) 2.23
A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol (2009) 2.14
Functional advantage after radical segmentectomy versus lobectomy for lung cancer. Ann Thorac Surg (2005) 2.06
Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest (2014) 1.98
Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg (2007) 1.65
Resection of chest wall invasion in patients with non-small cell lung cancer. Eur J Cardiothorac Surg (2004) 1.61
Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma. Ann Thorac Surg (2013) 1.51
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat (2010) 1.47
Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2004) 1.42
Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study. J Thorac Cardiovasc Surg (2011) 1.28
Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin. Jpn J Clin Oncol (2007) 1.28
Epidermal inclusion cyst of the breast. Breast Cancer (2007) 1.17
Carbon monoxide rescues ischemic lungs by interrupting MAPK-driven expression of early growth response 1 gene and its downstream target genes. Proc Natl Acad Sci U S A (2006) 1.14
Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother (2008) 1.10
Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: a multicenter study. Cancer (2010) 1.09
Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med (2013) 1.07
Dumbbell-shaped chondrosarcoma that primarily developed in the cervical spine: a case report. J Orthop Sci (2004) 1.07
Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: An international individual patient data meta-analysis. J Thorac Cardiovasc Surg (2009) 1.06
Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol (2011) 1.04
Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: significant correlation with poor prognosis. Cancer Lett (2006) 1.03
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol (2006) 1.01
Evaluation of optimal scan duration and end time in cerebral CT perfusion study. Radiat Med (2005) 1.01
Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings. J Thorac Cardiovasc Surg (2012) 1.00
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. Gan To Kagaku Ryoho (2009) 0.99
Expression of the TSLC1 adhesion molecule in pulmonary epithelium and its down-regulation in pulmonary adenocarcinoma other than bronchioloalveolar carcinoma. Lab Invest (2003) 0.98
PKCbeta regulates ischemia/reperfusion injury in the lung. J Clin Invest (2004) 0.98
Nodular pseudoangiomatous stromal hyperplasia of mammary stroma in a case showing rapid tumor growth. Breast Cancer (2005) 0.96
Contrast-enhanced CT evaluation of clinically and mammographically occult multiple breast tumors in women with unilateral early breast cancer. Jpn J Clin Oncol (2008) 0.95
A feasibility study of psychosocial group intervention for breast cancer patients with first recurrence. Support Care Cancer (2004) 0.95
Upregulation of notch2 and six1 is associated with progression of early-stage lung adenocarcinoma and a more aggressive phenotype at advanced stages. Clin Cancer Res (2011) 0.94
Advantage of absorbable suture material for pulmonary artery ligation. Gen Thorac Cardiovasc Surg (2010) 0.94
Metastatic Breast Cancer to the Stomach Resembling Early Gastric Cancer. Case Rep Oncol (2010) 0.94
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat (2014) 0.94
Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer. Jpn J Clin Oncol (2009) 0.93
Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery. Surg Today (2011) 0.93
A 40-year-old gossypiboma (foreign body granuloma) mimicking a malignant femoral surface tumor. Skeletal Radiol (2004) 0.92
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci (2011) 0.92
The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. J Thorac Cardiovasc Surg (2013) 0.92
Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. Jpn J Clin Oncol (2009) 0.91
Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery: report of a case. Surg Today (2012) 0.91
Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy. Case Rep Oncol (2010) 0.91
Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol (2009) 0.90
FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer (2011) 0.90
Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer (2008) 0.90
Synchronous liver metastases of intracystic papillary carcinoma with invasion of the breast. Breast Cancer (2005) 0.90
Cardiac imaging using 256-detector row four-dimensional CT: preliminary clinical report. Radiat Med (2007) 0.90
A case of small undifferentiated intramucosal gastric cancer with lymph node metastasis. Gastric Cancer (2010) 0.90
Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform. Oncogene (2004) 0.90
Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy? Breast Cancer (2012) 0.89
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol (2005) 0.89
Measurement of radiation dose in cerebral CT perfusion study. Radiat Med (2005) 0.89
Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat (2015) 0.89
Prognostic value of thermographical findings in patients with primary breast cancer. Breast Cancer Res Treat (2002) 0.88
Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Breast (2013) 0.88
Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys (2013) 0.88
Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg (2007) 0.87
Remitting seronegative symmetric synovitis with pitting edema: scintigraphic and magnetic resonance imaging findings. Clin Nucl Med (2003) 0.87
Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch (2010) 0.87
Bone metastasis detected by FDG PET in a patient with breast cancer and fibrous dysplasia. Clin Nucl Med (2005) 0.87
Increased ectodomain shedding of lung epithelial cell adhesion molecule 1 as a cause of increased alveolar cell apoptosis in emphysema. Thorax (2013) 0.87
Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results. Jpn J Clin Oncol (2011) 0.87
Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis. Surg Today (2010) 0.87
Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line. Oncol Rep (2008) 0.86
Widespread metastases from sarcomatoid renal cell carcinoma detected by (18)F-FDG positron emission tomography/computed tomography. Jpn J Radiol (2009) 0.86
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer (2012) 0.86
A complete remission of sclerosing rhabdomyosarcoma with multiple lung and bone metastases treated with multi-agent chemotherapy and peripheral blood stem cell transplantation (PBSCT): a case report. Anticancer Res (2008) 0.86
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Int J Clin Oncol (2013) 0.86
Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer (2012) 0.86
Technical feasibility and cosmetic advantage of hybrid endoscopy-assisted breast-conserving surgery for breast cancer patients. J Laparoendosc Adv Surg Tech A (2012) 0.85
Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project. EJNMMI Res (2013) 0.85
Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer. Pathobiology (2012) 0.85
Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int J Oncol (2009) 0.85
Evaluation of the number of SPECT projections in the ordered subsets-expectation maximization image reconstruction method. Ann Nucl Med (2003) 0.85
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer (2009) 0.85
Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer (2013) 0.85
Effect of x-ray tube current on the accuracy of cerebral perfusion parameters obtained by CT perfusion studies. Phys Med Biol (2005) 0.85
A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer (2006) 0.84
Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors. Jpn J Radiol (2012) 0.84
Laparoscopic thoracic duct clipping for persistent chylothorax after extrapleural pneumonectomy. Ann Thorac Surg (2012) 0.84
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. Cancer Sci (2013) 0.83
Influence of ischemic injury on vein graft remodeling: role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation. J Thorac Cardiovasc Surg (2005) 0.83
Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int J Cancer (2010) 0.83
Supraclavicular failure after breast-conserving therapy in patients with four or more positive axillary lymph nodes when prophylactic supraclavicular irradiation is omitted. Jpn J Radiol (2009) 0.83
No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan. Int J Clin Oncol (2008) 0.83
Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. J Proteome Res (2009) 0.83
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer (2010) 0.83
Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. Int J Cancer (2011) 0.83